Sun Pharmaceutical Industries Limited, commonly known as Sun Pharma, is committed to advancing patient care in psoriasis, alopecia areata, and acne. The company recently presented 14 abstracts at the 2026 AAD Annual Meeting held in Denver, Colorado, highlighting its ongoing research and development efforts in these areas.

Among the key products discussed, ILUMYA is focused on treating moderate-to-severe plaque psoriasis and nail psoriasis. Additionally, LEQSELVI is indicated for the treatment of severe alopecia areata, while WINLEVI is used for acne vulgaris and in combination therapies.

However, not all developments were positive. The Phase II FLASH study for Fibromun did not meet its primary endpoint for progression-free survival (PFS), raising questions about its future in the treatment landscape.

On a more promising note, Nidlegy achieved complete pathological responses in 52.6% of patients in the Phase II ‘Duncan’ study, indicating potential effectiveness in its application.

Furthermore, the GLIOSTELLA study, which focuses on late-line glioblastoma, has completed enrollment in the U.S., marking a significant step forward in this area of research.

Sun Pharma is also preparing a new submission for Nidlegy after withdrawing a prior Marketing Authorization Application in 2025. This move reflects the company’s commitment to advancing its product portfolio despite previous setbacks.

Dr. Ahmad Naim commented on the presentations, stating, “The data we are presenting at AAD underscore our commitment to advancing dermatology and immunology through meaningful science – spanning not only clinical efficacy and safety, but also how these therapies perform over time and in real-world practice.”

As observers look ahead, the focus will be on how these developments will influence treatment options and patient outcomes in the dermatology field.

Details remain unconfirmed.

The post Sun Pharma Advances Dermatology Research at AAD Annual Meeting appeared first on newscri.